Compare FUL & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUL | VERA |
|---|---|---|
| Founded | 1887 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.4B |
| IPO Year | N/A | 2021 |
| Metric | FUL | VERA |
|---|---|---|
| Price | $67.25 | $42.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $70.20 | ★ $76.60 |
| AVG Volume (30 Days) | 430.5K | ★ 1.0M |
| Earning Date | 03-25-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 19.57 | N/A |
| EPS | ★ 2.75 | N/A |
| Revenue | ★ $3,473,589,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | $24.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.56 | $18.53 |
| 52 Week High | $68.63 | $56.05 |
| Indicator | FUL | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 41.78 |
| Support Level | $64.94 | $41.46 |
| Resistance Level | $68.63 | $44.96 |
| Average True Range (ATR) | 1.78 | 2.22 |
| MACD | 0.52 | -0.31 |
| Stochastic Oscillator | 88.57 | 19.07 |
H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Construction Adhesives. It generates the maximum revenue from hygiene, health, and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based, and solvent-based products for applications in various markets, including packaging, converting, nonwoven, and hygiene (disposable diapers, feminine care, and medical garments) and health and beauty. The company generates around half of its revenue in the United States.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.